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Abstract
Introduction
Interstitial lung disease (ILD) is a heterogeneous group of over 200 parenchymal lung diseases with a myriad
of etiologies. Interstitial lung disease registries from around the world show varying prevalence and
incidence of these diseases. The aim of this study was to determine the epidemiology and characteristics of
ILD in Pakistan.

Methods
This web-based registry, which is the first multicenter registry of ILD from Pakistan, recruited patients from
10 centers of five major cities between January 2016 and March 2019.

Results
A total of 744 patients were enrolled in the registry. The five most frequent ILDs were idiopathic pulmonary
fibrosis (IPF) 34.4%, hypersensitivity pneumonitis (HP) - 17.7%, idiopathic nonspecific interstitial
pneumonitis (iNSIP) - 16.8%, connective tissue disease-associated ILD (CTD-ILD) - 16.3%, and sarcoidosis 9.1%.

Conclusion
Idiopathic pulmonary fibrosis is the most prevalent ILD in Pakistan, followed by HP and iNSIP. An ongoing
prospective registry with longitudinal follow-up will help us further elaborate on the clinical characteristics,
treatment, and survival outcome of patients with ILD.
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Introduction
The term interstitial lung disease (ILD) encompasses a group of heterogeneous diseases that affect the lung
parenchyma. The etiology of the disease is diverse. Two thirds of all ILD are idiopathic, most common of
these is idiopathic pulmonary fibrosis (IPF) and idiopathic non-specific interstitial pneumonitis (iNSIP).
Other causes of ILD may be secondary to environmental and occupational exposures as in hypersensitivity
pneumonitis (HP) or as a manifestation of connective tissue disease (CTD) [1]. The diagnosis of ILD is often
complex and requires a multi-disciplinary approach involving a team of pulmonologists, radiologists,
pathologists, and rheumatologists in selected cases.
Although several worldwide epidemiologic studies on ILD have been carried out, the data from these studies
is variable, partially dependent on the diagnostic criteria used [2-4]. Additionally, differences in geographic
and ethnic populations may also play a role. Most epidemiologic studies on ILD have been conducted in
Western countries, although data from the Eastern hemisphere is on the rise.
Serially published data between 2008 and 2016 on the relative frequencies of ILD limited to few centers from
Pakistan suggests that 30 to 40 percent of reported ILD cases were IPF [5-9]. The second recently published
report derives its data from the ongoing prospective national registry from multiple geographical locations
of Pakistan documenting the epidemiology and characteristics of ILD [10]. This study includes the updated
data of further three months subsequent to this report. The aim of this study was to describe the
epidemiology and characteristics of ILD using the first multicenter web-based registry of Pakistan.
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This article was previously presented as an abstract at the CHEST Annual Meeting on October 18-21, 2020.

Materials And Methods
In this prospective national registry under the supervision of the Pakistan Chest Society (PCS), recruitment
of participants was done from January 2016 till March 2019. A total of 10 centers from five major cities
across Pakistan participated in the registry (Figure 1).

FIGURE 1: Recruitment from Different Centres of Pakistan
AKUH=Aga Khan University Hospital, DP=Doctors Plaza, DUHS=Dow University of Health Sciences,
SZH=Sheikh Zayed Hospital, KEMU=King Edward Medical University, NMCU=Nishtar Medical College,
GDCH=Gulab Devi Chest Hospital, KTH=Khyber Teaching Hospital, LRH=Lady Reading Hospital,
FJCGH=Fatema Jinnah Chest & General Hospital

The Independent Ethics Committee Approval (Ref. No. MU/ECA/99/861/R-2) was obtained for all
participating centers and they were requested to assign a principal investigator (PI) who was responsible for
patients’ registration. The PI was required to furnish a written high-resolution computed tomography
(HRCT) report from a radiologist trained in reading HRCT relevant to ILD. A written histopathology report
was to be provided in cases where a biopsy was performed. The opinion of rheumatologists was also sought
in cases of CTD-related ILD. The purpose of this multidisciplinary discussion (MDD) resource group was to
maintain uniformity in the diagnostic criteria.
The questionnaire was specifically designed for the registry. After obtaining the written informed consent,
patients more than or equal to 18 years of age with relevant history and HRCT images of the chest consistent
with ILD were included. Data was gathered on demographics, occupation, history of environmental
exposure, comorbids like diabetes, hypertension, chronic obstructive pulmonary disease (COPD),
gastroesophageal reflux disease (GERD), history of drugs that can cause ILD like bleomycin, amiodarone,
methotrexate, or cyclophosphamide and family history of ILD. Findings of HRCT scans, serology for CTDILD, and pulmonary function tests (PFTs), mainly consisting of spirometry and diffusing capacity of the
lungs for carbon monoxide (DLCO) in a few cases, were recorded. Active lung parenchymal infections like
pulmonary tuberculosis (TB) were ruled out by sputum or bronchoalveolar lavage (BAL) for acid-fast bacillus
(AFB) smear, Gene-Xpert, and culture when there was a high clinical suspicion of infection. Patients with a
clinical history of previous tuberculosis, lung carcinoma and history of exposure to radiation were excluded
from the registry. The electronic copy of questionnaire was uploaded on an online database
(http://pcsregistry.ildpak.com/public/login) while the physician retained a hard copy of the questionnaire as
a source document.
Data was analyzed through Statistical Package for Social Sciences (SPSS) version-22 (IBM Corp, Armonk, NY,
USA). Descriptive statistics was presented as mean±standard deviation for numerical data and frequencies
percentages for categorical data. Analysis of variance (ANOVA) and Chi-square test of significance were
applied to evaluate the association between type of ILD and study variables. P-value <0.05 was considered
statistically significant.

Results
A total of 744 patients were enrolled in the registry. The final ILD diagnoses were as follows: IPF 256
(34.4%), HP 132 (17.7%), iNSIP 125 (16.8%), CTD-ILD 121 (16.3%), sarcoidosis 68 (9.1%) and 42 (5.7%), and
other ILD (Table 1).
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Types of ILD

n (n%)

IPF

256 (34.4%)

CPFE

11 (1.5%)

HP

132 (17.7%)

iNSIP

125 (16.8%)

CTD-ILD

121 (16.3%)

RA

56 (7.5%)

SD

25 (3.4%)

MCTD

14 (1.9%)

SLE

13 (1.7%)

PM/DM

11 (1.5%)

SS

2 (0.3%)

Sarcoidosis

68 (9.1%)

Others

42 (5.7%)

COP/BOOP

15 (2%)

Drug Induced ILD

6 (0.8%)

Methotrexate

3 (0.4%)

Cyclophosphamide

2 (0.3%)

Interferon

1 (0.1%)

IPAF

5 (0.7%)

PAP

3 (0.4%)

PLCH

2 (0.3%)

LAM

2 (0.3%)

RB-ILD

2 (0.3%)

Silicosis

2 (0.3%)

CWP

1 (0.1%)

DIP

1 (0.1%)

AIP

1 (0.1%)

BO

1 (0.1%)

Undetermined ILD

1 (0.1%)

TABLE 1: Relative Frequencies of Interstitial Lung Diseases in ILD Registry
ILD=Interstitial Lung Disease, IPF=Idiopathic Pulmonary Fibrosis, HP=Hypersensitivity Pneumonitis, iNSIP=Idiopathic Nonspecific Interstitial
Pnuemonitis, CTD-ILD=Connective Tissue Disease Associated ILD, CPFE=Combined Pulmonary Fibrosis with Emphysema, RA=Rheumatoid
Arthritis, SD=Scleroderma, MCTD=Mixed Connective Tissue Disease, SLE=Systemic Lupus Erythematosus, PM/DM=Polymyositis/Dermatomyositis,
SS=Sjögren's Syndrome, COP/BOOP=Cryptogenic Organizing Pneumonia/Bronchiolitis Obliterans Organizing Pneumonia, IPAF=Interstitial
Pneumonia with Autoimmune Features, PAP=Pulmonary Alveolar Proteinosis, PLCH=Pulmonary Langerhans Cell Histiocytosis,
LAM=Lymphangioleiomyomatosis, RB-ILD=Respiratory Bronchiolitis ILD, CWP= Coal Worker’s Pneumoconiosis, DIP=Desquamative Interstitial
Pneumonia, AIP=Acute Interstitial Pneumonia, BO=Bronchiolitis Obliterans

The median age was 57.5 years with interquartile range 46-65 years and gender was predominantly female
(65.6%). Overall, 679 (91.3%) patients lived in urban areas. IPF patients were older (>60 years) and with
history of current or past smoking with statistical significance (P<0.001). All ILD, except for IPF, had a
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statistically higher proportion of females (P<0.001). The most common clinical symptoms were cough in 674
(90.6%) and dyspnea in 519 (69.75%). On physical examination, crepitations were audible in 674 (90.6%) and
rhonchi in 83 (11.2%) while clubbing was seen in 247 (33.2%). Gastroesophageal reflux disease (GERD) was
present in 195 (26.2%) patients and was statistically significant with iNSIP and IPF (P=0.021).
Echocardiography was done in 432 (58.1%) patients, of which 206 (47.7%) showed pulmonary arterial
hypertension (PAH); 44.7% had mild PAH, 30.1% had moderate PAH and 25.2% had severe PAH (Table 2).

Age in years; mean ±SD

Overall

IPF/UIP (n=

HP

iNSIP

CTD-ILD

Sarcoidosis

Others

P-

(n=744)

256)

(n=132)

(n=125)

(n=121)

(n=68)

(n=42)

value

56.2 ±13.9

64.5 ±11.8

51.6
±13.5

55.4
±11.7

50.3 ±12.1

50.3 ±12.7

48.4 ±15.5

˂0.001

256
(34.4%)

139 (54.3%)

34
(25.8%)

23
(18.4%)

12 (9.9%)

23 (33.8%)

25 (59.5%)

98

102

(74.2%)

(81.6%)

109 (90.1%)

45 (66.2%)

17 (40.5%)

8 (6.1%)

15 (12%)

5 (4.1%)

3 (4.4%)

2 (4.8%)

110 (88%)

116 (95.9%)

65 (95.6%)

40 (95.2%)

9 (6.8%)

9 (7.2%)

8 (6.6%)

5 (7.4%)

15 (35.7%) ˂0.001

43

37

(32.6%)

(29.6%)

30 (24.8%)

8 (11.8%)

8 (19%)

˂0.001

112 (43.8%)

40
(30.3%)

59
(47.2%)

46 (38%)

23 (33.8%)

8 (19%)

0.003

72 (28.1%)

37 (28%)

24 (19.8%)

21 (30.9%)

8 (19%)

0.003

30 (11.7%)

3 (2.3%)

6 (4.8%)

2 (1.7%)

3 (4.4%)

4 (9.5%)

0.001

35

39

(26.5%)

(31.2%)

29 (24%)

8 (11.8%)

7 (16.7%)

0.021

86
(65.2%)

76
(60.8%)

78 (64.5%)

22 (32.4%)

21 (50%)

˂0.001

39

46

(45.3%)

(60.5%)

29 (37.2%)

9 (40.9%)

6 (28.6%)

0.023

17

22

(43.6%)

(47.8%)

9 (31%)

4 (44.4%)

3 (50%)

13
(28.3%)

13 (44.8%)

1 (11.1%)

4 (44.4%)

11
(23.9%)

7 (24.1%)

4 (44.4%)

2 (33.3%)

Gender; n (%)
Male

Female

488
(65.6%)

117 (45.7%)

˂0.001

Area of Living; n (%)
Rural
Urban

Smoking History; n (%)

Clubbing; n (%)

Hypertension; n (%)

Diabetes Mellitus; n (%)
COPD; n (%)
GERD; n (%)

Echocardiography; n (%)

PAH (n=432); n (%)

65 (8.7%)
679
(91.3%)
113
(15.2%)
247
(33.2%)
288
(38.7%)
215
(28.9%)
48 (6.5%)
195
(26.2%)
432
(58.1%)
206
(47.7%)

32 (12.5%)
224 (87.5%)

67 (26.2%)

121 (47.3%)

77 (30.1%)

149 (58.2%)

77 (51.7%)

124
(93.9%)

53
(42.4%)

0.023

Severity of PAH (mPAP)
(n=206); n (%)
Mild (25 – 40 mmHg)

92 (44.7%)

37 (48.1%)

0.508
Moderate (41 – 55 mmHg)

62 (30.1%)

19 (24.7%)

15
(38.5%)

Severe (> 55 mmHg)

52 (25.2%)

21 (27.3%)

7
(17.9%)

TABLE 2: Demographics and Clinical Features of ILD
ILD=Interstitial Lung Disease, IPF=Idiopathic Pulmonary Fibrosis, UIP=Usual Interstitial Pneumonia, HP=Hypersensitivity Pneumonitis,
iNSIP=Idiopathic Nonspecific Interstitial Pnuemonitis, CTD-ILD=Connective Tissue Disease Associated ILD, COPD=Chronic Obstructive Pulmonary
Disease, GERD=Gastroesophageal Reflux Disease, PAH=Pulmonary Arterial Hypertension, mPAP=Mean Pulmonary Arterial Pressure
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The overall predicted forced vital capacity (FVC) was 58.2 ±18.7%. FVC % of predicted was presented as boxand-whiskers plot showing the median, interquartile range and outliers (if any) for ILD patients. The median
FVC for IPF was 59 (range: 25-99.99), for iNSIP was 54 (range: 25-99.99), for CTD-ILD was 60.5 (range: 2699.99), for sarcoidosis it was 67 (range: 26-99.99). The HP patients had the lowest FVC % of predicted
median that was 45.5 (range: 25-82) where four cases had ≥85 FVC and considered as outliers (Figure 2). An
avian exposure was reported in 105 (79.5%) HP patients and out of which 86.8% were females (Figure 3).

FIGURE 2: Gender-wise Exposure in Patients with Hypersensitivity
Pneumonitis

FIGURE 3: Box and Whisker Plot of Forced Vital Capacity (% of
predicted) in Different ILDs
FVC=Forced Vital Capacity, ILD=Interstitial Lung Disease

Discussion
IPF accounted for the highest proportion of reported ILD which is 34.4% in our registry. This finding is
consistent with earlier local published data [8, 9]. IPF was diagnosed between 28.6% to 46% among ILD in
various studies reported from India [11]. The ILD-India Registry however reported 13.7% IPF which is
considerably lesser than their earlier data. Interestingly, the diagnosis of IPF (28.2%) among ILD was highest
in their onsite reporting which was reduced to 13.7% by ILD experts from the US [4]. The data from a singlecenter study in Saudi Arabia reported IPF in 23.3% of patients while the Romanian, Turkish, and Greek
registries showed a prevalence of IPF in 25%, 19.9%, and 19.5%, respectively [12-15]. In our registry, IPF was
predominantly found in males and those greater than 65 years of age as reported worldwide [4, 12, 14-16].
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The second most common ILD in our registry was HP (17.7%) whereas it accounted for the majority in the
Indian registry (47.3%) [4]. Most other ILD registries have reported the prevalence of HP to be 3-13% [17, 18].
It has been gaining more proportion in our population from 4% to 17.7% in last 10 years. This could either be
its true incidence due to an increase in environmental allergens or a better recognition of chronic fibrosing
HP from IPF which is comparable to results from regional data [4-9]. In our population, 79.5% had an avian
exposure which was more predominant in housewives reflecting significant avian antigen in the household
environment. The data from the Japanese epidemiological survey also presented 60.4% while the Indian
registry showed 21.4% of avian exposure [4, 19].
We have seen iNSIP (16.8%) and CTD-related ILD (16.3%) as the next two most frequent ILD in our registry.
CTD-ILD was also the second common ILD in the Indian registry (13.9%) with rheumatoid arthritis (RA)
being the commonest subtype followed by scleroderma which is similar to our findings [4]. Females were
found to be significantly higher in iNSIP (81.6%) & CTD-ILD (90.1%) in comparison with other ILD. In CTDILD, females under the mean age of 50 years were predominant which is consistent with an international
data [20].
Sarcoidosis was found in 9.1% which is much less than in earlier studies from Pakistan which reported 15.3%
to 18.5% [5, 6, 9]. This difference could be attributed to misdiagnoses of sarcoidosis where it might be
considered as a sequela of pulmonary tuberculosis in high TB burden countries [18].
There could be several limitations in our ILD Registry. The current data was collected from major urban cities
of Pakistan which does not represent our rural population. The lack of use of a detailed questionnaire
pertaining to the history of exposures and the non-availability of serum precipitins to identify inducers
might have led to an underdiagnosis of HP. Differentiating fibrotic HP from IPF has generally remained a
difficult task as well.
Another limitation in our registry was the scarcity of histopathological confirmation attributable to a
number of factors. The majority of cases were IPF which do not require lung biopsy while the iNSIP and HP
presented with severely restricted lung function.

Conclusions
Registry data from Pakistan concludes that IPF was the most common ILD followed by HP, iNSIP, CTD related
ILD and sarcoidosis. There has been slight variation in the relative frequencies obtained from various
geographic areas of this populous country, but most values have been in line with earlier studies. An
expansion of the ILD registry to other cities and rural areas of the country with longitudinal follow-up of
currently enrolled patients and more stringent validation of data by MDD in tertiary care and National
Coordinating Centers could further expand the network and refine disease information.
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